Back to Search
Start Over
702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 9
- Issue :
- Suppl 2
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9071b57c428b46788ed7f93d7993e7d0
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2021-SITC2021.702